7Baggers
 Brokers Set Expectations for PRLD Q3 Earnings  Defense World Fri, 26 Sep 2025 05:07:56 GMT
 analysts offer predictions for prld q3 earnings  MarketBeat Thu, 25 Sep 2025 12:20:27 GMT
 New PROTACs revealed in Prelude Therapeutics patent  BioWorld MedTech Mon, 22 Sep 2025 13:00:00 GMT
 Prelude Therapeutics Regains Nasdaq Compliance  TipRanks Fri, 19 Sep 2025 07:00:00 GMT
 published on: 2025-09-11 05:01:05  Newser Thu, 11 Sep 2025 10:01:05 GMT
 published on: 2025-09-11 01:51:05  Newser Thu, 11 Sep 2025 06:51:05 GMT
 published on: 2025-09-06 20:49:10  Newser Sun, 07 Sep 2025 01:49:10 GMT
 published on: 2025-09-06 13:48:12  Newser Sat, 06 Sep 2025 18:48:12 GMT
 published on: 2025-09-03 02:57:37  Newser Wed, 03 Sep 2025 07:57:37 GMT

Prelude Therapeutics Incorporated
(NASDAQ:PRLD) 

PRLD stock logo

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid...

Founded: 2016
Full Time Employees: 55
CEO: Krishna Vaddi  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends